ORALMEDIC® Barrier Solution is the only OTC product available in the world that immediately and permanently ends oral ulcer pain with one ten-second treatment. Canada joins the U.K. as the first countries offering the product to their consumers. Approval to release the product in the United States is currently pending FDA regulatory review.

Commenting on the need for such a product in the market place Steve Corrick, President of Corum Marketing, noted “There are no other products like this one and we are pleased to be part of its early distribution with EPIEN.”

EPIEN’s CEO Reginald Dupre stated that “We are excited to follow our spring U.K. release of ORALMEDIC® Barrier Solution with this fall’s release in Canada. We look forward to success with the Axel Kraft/Corum Marketing relationship.”

EPIEN Medical is a privately held medical device company focused on developing, manufacturing, and marketing novel agents for the repair of damaged skin. The Company’s initial approved products treat oral ulcers by quickly and permanently relieving pain by cleansing and sealing the lesion with a single, easy-to-use, ten-second treatment.

Additional corporate information is available at www.epien.com.

The UK OTC distribution, expected to begin early next year, represents the first time that HybenX™ will be available directly to consumers. The product was previously available only through dental and medical professionals. Europe has an incidence of mouth ulcers (canker sores) similar to the US with about 20% of the population, or about 75 million people, suffering from ulcers on a recurrent basis. The global mouth ulcer market is valued at approximately $250 million.

EPIEN’s HybenX™ technology is the only treatment available that provides immediate and long-lasting pain relief with a single application. The product is supplied in an easy-to-use, single-use applicator swab.

Boots Group PLC operates Boots the Chemists, the UK’s leading drugstore chain with about 1,400 shops in Britain and Ireland, sells OTC drugs in 130 countries. Overall group revenue exceeded $10 Billion in the fiscal year ended March 2005.

EPIEN Medical is a privately held medical device company focused on developing, manufacturing, and marketing novel wound care agents based on proprietary chemical formulations.

Galpharm International Limited is a privately held British company located in South Yorkshire and is a leader in Private Label and Branded OTC Medicines in the UK with a growing reputation for bringing innovative products to the self-medication market.

Additional corporate information is available at www.epien.com.